Why the study?
Does non-vitamin K antagonist oral anticoagulant therapy reduce the duration of hospital stay and medical costs compared to warfarin in patients with cardiogenic embolism stroke discharged to home?
Observational (n=159)
No
Does non-vitamin K antagonist oral anticoagulant therapy reduce the duration of hospital stay and medical costs compared to warfarin in patients with cardiogenic embolism stroke discharged to home?
NOAC therapy in the acute phase of cardiogenic embolic stroke is associated with shorter hospital stays and lower medical costs compared to warfarin.
Answers are grounded in this paper and cite their sources.
May shorten stays with NOACs in embolic stroke; hypothesis-generating and requires RCT confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Deguchi et al. (2015) conducted an observational in Cardiogenic embolism stroke (n=159). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin was evaluated on Duration of hospital stay (days) (OR 0.168, 95% CI 0.074-0.382, p=<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: